Cardiology pp 91-105 | Cite as

Treatment of Cardiomyopathies

  • J. F. Goodwin


In order to advise rational treatment it is necessary to define and to classify the conditions known as cardiomyopathies. Cardiomyopathies are defined as “Heart Muscle Diseases of Unknown Causes” to distinguish them from myocardial diseases due to disorders of other systems; the “Specific Heart Muscle Diseases”. This lecture is concerned with the treatment of cardiomyopathies so defined.


Mitral Regurgitation Infective Endocarditis Hypertrophic Cardiomyopathy Ventricular Volume Mitral Valve Replacement 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alvares, R., 1980, Diastolic function and prognosis in hypertrophic cardiomyopathy, PhD Thesis, University of London.Google Scholar
  2. Braimbridge, M. V., Darracott, S., Chayen, J., Bitensby, L., Poulter, L. W., 1967, Possibility of a new infective etiological agent in congestive cardiomyopathy, Lancet, 1:171–176.PubMedCrossRefGoogle Scholar
  3. Cambridge, G., MacArthur, C. G. C., Waterson, A. P., Goodwin, J. F., Oakley, C. M., 1979, Antibodies to Coxsackie B virus in congestive cardiomyopathy, Brit. Heart J., 41:692.PubMedCrossRefGoogle Scholar
  4. Criley, J. M. et al., 1965, Pressure gradients without obstruction: a new concept of hypertrophic subaortic stenosis, Circulation, 32:881.PubMedCrossRefGoogle Scholar
  5. Davies, J., Sapsford, R., Tai, P. C., Spry, C. J. F., Goodwin, J. F., 1981, Löffler’s endomyocardial disease — cardiological and immunological study of nine patients with report of successful surgery in three patients, Brit. Heart J., 45:338 (P).CrossRefGoogle Scholar
  6. Dubost, C., Marine, P., Gerbaux, A., Bertrand, E., Rulliere, R., Vial, F., Barrillon, A., Prigent, C., Carpenter, A., Soyer, R., 1976, Surgical treatment of constrictive fibrous endocarditis, Ann. Surg., 184:303–307.PubMedCrossRefGoogle Scholar
  7. Fitchett, D. H., Marin Neto J. A., Oakley, C. M., Goodwin, J. F., 1979, Hydrallazine in the assessment of left ventricular failure, Amer. J. Cardiol., 44:30.CrossRefGoogle Scholar
  8. Fowler, B. B., Bieber, C. P., Stinson, E. B., 1979, Defective in vitro suppressor cell dysfunction in idiopathic congestive cardiomyopathy, Circulation, 59:483.CrossRefGoogle Scholar
  9. Frank, M. J. et al., 1978, Long term medical management of hypertrophic obstructive cardiomyopathy, Amer. J. Cardiol., 42:993.PubMedCrossRefGoogle Scholar
  10. Fuster, V. et al., 1982, Idiopathic dilated congestive cardiomyopathy — observations on the natural history, in: “Congestive Cardiomyopathy”, eds., Goodwin, J. F., Hjalmarsson, A. and Olsen, E. G. J., Hessle, Molndal, Sweden, p. 208.Google Scholar
  11. Goodwin, J. F., Oakley, C. M., 1972, The Cardiomyopathies, Brit. Heart J., 34:595.CrossRefGoogle Scholar
  12. Goodwin, J. F., 1974, International Lecture: Prospects and predictions for the cardiomyopathies, Circulation, 50:210.PubMedCrossRefGoogle Scholar
  13. Goodwin, J. F., Krikler, D. M., 1976, Arrhythmia as a cause of sudden death in hypertrophic cardiomyopathy, Lancet, 2:937–940.PubMedCrossRefGoogle Scholar
  14. Goodwin, J. F., 1979, Cardiomyopathy: an interface between fundamental and clinical cardiology, in: “Cardiology”, ed., Hayase and Murao, Excerpta Medica Amsterdam, p. 103.Google Scholar
  15. Goodwin, J. F., 1981, The frontiers of cardiomyopathy, Brit. Heart J., to be published.Google Scholar
  16. Goodwin, J. F., 1982, The frontiers of cardiomyopathy, Brit. Heart J., in press.Google Scholar
  17. Hubner, P. J. B., Ziady, G. M., Raine, G. K., Hardarson, T., Scales, B., Oakley, C. M., Goodwin, J. F., 1973, Double blind trial of Propranolol, and Practolol in hypertrophic cardiomyopathy, Brit. Heart J., 35:1116.PubMedCrossRefGoogle Scholar
  18. Kaltenbach, M., Hopf, R., Kober, G., Bussman, W.-D., Keller, M., Peterson, Y., 1979, Treatment of hypertrophic obstructive cardiomyopathy with Verapamil, Brit. Heart J., 42:35–42.PubMedCrossRefGoogle Scholar
  19. Kawii, C., 1971, Idiopathic cardiomyopathy. A study on the infection/ immune theory as a cause of the disease, Jap. Circ. J., 35:765.CrossRefGoogle Scholar
  20. Kuhn, H., Krelhaw, W., Bircks, W., Schulte, H. D., Loogen, F., 1978, Indication for surgical treatment in patients with hypertrophic obstructive cardiomyopathy, in: “Cardiomyopathy and myocardial biopsy”,Eds., Kaltenbach, Loogen, Olsen, Springer Verlag, Berlin, p. 308.CrossRefGoogle Scholar
  21. Lorell, B. H., Poulus, Grossman, W., Fulton, M. A., Wynne, J., Cohn, P. F., 1980, Improved diastolic compliance in hypertrophic cardiomyopathy treated with Nifedipine, Circulation, 3:62, 317.Google Scholar
  22. MacArthur, C. G. C. et al., 1982, The effect of left ventricular function, arrhythmias and evidence of previous viral infection on the prognosis of congestive cardiomyopathy, in: “Congestive Cardiomyopathy”, eds., Goodwin, J. F., Hjalmarsson, A. and Olsen, E. G. J., Hessle, Molndal, Sweden, p. 236.Google Scholar
  23. McKenna, W. J., Chetty, S., Oakley, C. M., Goodwin, J. F., 1980, Arrhythmias in hypertrophic cardiomyopathy; exercise electrocardiogram and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy, Amer. J. Cardiol., 45:1–5.PubMedCrossRefGoogle Scholar
  24. McKenna, W. J., England, D., Doi, Y. C., Deanfield, J. E., Oakley, C. M., Goodwin, J. F., 1981<sup>a</sup>, Arrhythmias in hypertrophic cardiomyopathy: I, influence on prognosis, Brit. Heart J., in press.Google Scholar
  25. McKenna, W., Deanfield, J., Faruqui, A., England, D., Oakley, C., Goodwin, J. F., 1981b, Prognosis in hypertrophic cardiomyopathy. Role of age and clinical electrocardiographic and hemodynamic features, Amer. J. Cardiol., 47:532.PubMedCrossRefGoogle Scholar
  26. McKenna, W. J., Harris, L., Perez, G., Krikler, D. M., Oakley, C. M., Goodwin, J. F., 1981<sup>c</sup>, Arrhythmias in hypertrophic cardiomyopathy: II, comparison of Amiodarone and Verapamil in treatment, Brit. Heart J., in press.Google Scholar
  27. Maron, B. J., Merrill, W. H., Freier, P. A., Kent, K. M., Epstein, S. E., Morrow, A. G., 1978, Long term clinical course and symptomatic status of patients after operative treatment for hypertrophic subaortic stenosis, Circulation, 57:1205.PubMedCrossRefGoogle Scholar
  28. Maron, B. J., Lipson, L. C., Roberts, W. C., Savage, D. D., Epstein, S. E., 1978a, ‘Malignant’ hypertrophic cardiomyopathy, Amer. J. Cardiol., 41:1133–1140.PubMedCrossRefGoogle Scholar
  29. Maron, B. J., Epstein, S. E., Roberts, W. C., 1979, Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary artery, Amer. J. Cardiol., 43:1086–1102.PubMedCrossRefGoogle Scholar
  30. Mason, J. W., Billingham, M. E., Ricci, D. R., 1980, Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy, Amer. J. Cardiol., 45:1037.PubMedCrossRefGoogle Scholar
  31. Murgo, J. P., et al., 1980, Dynamics of left ventricular ejection in obstructive and non-obstructive hypertrophic cardiomyopathy, Amer. J. Cardiol., 45:6.CrossRefGoogle Scholar
  32. Reitz, B. A., Epstein, S. E., Henry, W. L., Conkle, D. M., Iskoitz, S. B., Redwood, B. R., Morrow, A. G., 1975, Operative treatment in hypertrophic subaortic stenosis. Techniques and the results of pre and post operative assessment in 83 patients, Circulation, 52:88.PubMedCrossRefGoogle Scholar
  33. Report of the WHO/ISFC Task Force on the Definition and Classif ication of cardiomyopathies, Brit. Heart J., 1972, 34:545.Google Scholar
  34. Rosing, D. R., Kent, K. M., Borer, J. S., Seides, S. F., Maron, B. J., Epstein, S. E., 1979 a, Verapamil therapy: A new approach to the pharmacological treatment of hypertrophic cardiomyopathy; I, hemodynamic effects, Circulation, 60:1201.Google Scholar
  35. Rosing, D. R., Kent, K. M., Maron, B. J., Epstein, S. E., 1979b, Verapamil therapy: A new approach to the pharmacological treatment of hypertrophic cardiomyopathy; II, effects on exercise capacity and symptomatic status, Circulation, 60:1208–1213.PubMedCrossRefGoogle Scholar
  36. Rosing, D. R. et al., 1981, Verapamil therapy: a new approach to the pharmacological treatment of hypertrophic cardiomyopathy; III, the effect of long term administration, Amer. J. Cardiol., 48:545.PubMedCrossRefGoogle Scholar
  37. Sanderson, J. E., Traill, T. A., Sutton, M. G. St.J., Brown, D. J., Gibson, D. G., Goodwin, J. F., 1978, Left ventricular relaxation and filling in hypertrophic cardiomyopathy. An echocardiographic study, Brit. Heart J., 40:596.PubMedCrossRefGoogle Scholar
  38. Sharma, B., Goodwin, J. F., 1978, Beneficial effects of Salbutamol on cardiac function in severe congestive cardiomyopathy. Effects on systolic and diastolic function of the left ventricle, Circulation, 58:449.PubMedCrossRefGoogle Scholar
  39. Sharpe, D. N. et al., 1980, Low dose Captopril in chronic heart failure: acute hemodynamic effect and long term treatment, Lancet, 2:1154.PubMedCrossRefGoogle Scholar
  40. Spry, C. J. F., Tai, P. C., 1976, Studies in blood eosinophils. II, patients with Löffler’s cardiomyopathy, Clin. Exper. Immunol., 24:423.Google Scholar
  41. Swanton, R. H. et al., 1977, Haemodynamic studies of beta blockade in hypertrophic cardiomyopathy, Europ. J. Cardiol., 5:327.Google Scholar
  42. Waa stein, F., Hjalmasson, A., Vonrausker, E., Wolenkin, I., 1975, Effect of clinical beta adrenergic blockade in congestive cardiomyopathy, Brit. Heart J., 37:1022.CrossRefGoogle Scholar
  43. Webb-Peploe, M. M., Croxson, R. S., Oakley, C. M., Goodwin, J. F., 1971, Cardioselective beta adrenergic blockade in hypertrophic obstructive cardiomyopathy, Postgrad. Med. J., (suppl.), 47:93–97.Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • J. F. Goodwin
    • 1
  1. 1.Royal Postgraduate Medical SchoolLondonUK

Personalised recommendations